INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Elevance Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - ELV

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit involves claims that Elevance and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance and Market Reaction - On July 17, 2024, Elevance's CEO reported a shift in Medicaid membership mix leading to increased acuity, resulting in a stock price drop of $32.21 per share, or 5.8$520.93 [4]. - During the October 17, 2024, earnings call, the CEO disclosed that adjusted diluted earnings per share for the third quarter were $8.37, below expectations due to elevated medical costs in Medicaid, causing a stock price decline of$52.61 per share, or 10.6%, closing at $444.35 [5]. - The full-year outlook for adjusted diluted earnings per share was reduced from$37.20 to approximately $33, despite previous guidance just three months earlier [5].